Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2016) WHO classification of tumours of the central nervous system. International Agency for Research on Cancer, Lyon
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of tumours of the central nervous system. International Agency for Research on Cancer, Lyon
Zulch KJ (1979) Histological typing of tumours of the central nervous system. Switzerland, Geneva
Kleihues P, Burger P, Scheithauer BW (1993) Histological typing of tumours of the central nervous system. Springer, Berlin
Kleihues P, Cavenee W (2000) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon
Giannini C, Burger P, Berkey BA et al (2008) Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 18(3):360–369
Ezaki T, Sasaki H, Hirose Y, Miwa T, Yoshida K, Kawase T (2011) Molecular characteristics of pediatric non-ependymal, non-pilocytic gliomas associated with resistance to temozolomide. Mol Med Rep 4(6):1101–1105
Hayashi S, Sasaki H, Kimura T et al (2015) Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort. Oncotarget 6(18):15871–15881
Koelsche C, Wohrer A, Jeibmann A et al (2013) Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 125(6):891–900
Nakagawa Y, Sasaki H, Ohara K et al (2017) Clinical and molecular prognostic factors for long-term survival of patients with glioblastomas in single-institutional consecutive cohort. World Neurosurg 106:165–173
Hirose Y, Aldape K, Takahashi M, Berger MS, Feuerstein BG (2001) Tissue microdissection and degenerate oligonucleotide primed-polymerase chain reaction (DOP-PCR) is an effective method to analyze genetic aberrations in invasive tumors. J Mol Diagn 3(2):62–67
Miwa T, Hirose Y, Sasaki H, Ezaki T, Yoshida K, Kawase T (2011) Single-copy gain of chromosome 1q is a negative prognostic marker in pediatric nonependymal, nonpilocytic gliomas. Neurosurgery 68(1):206–212
Saotome K, Chiyoda T, Aimono E et al (2020) Clinical implications of next-generation sequencing-based panel tests for malignant ovarian tumors. Cancer Med 9(20):7407–7417
Aimono E, Nishihara H (2020) Required human and system resources for genomic medicine. Yakugaku Zasshi 140(5):651–655
Makabe T, Arai E, Hirano T et al (2019) Genome-wide DNA methylation profile of early-onset endometrial cancer: its correlation with genetic aberrations and comparison with late-onset endometrial cancer. Carcinogenesis 40(5):611–623
Ohara K, Arai E, Takahashi Y et al (2018) Feasibility of methylome analysis using small amounts of genomic DNA from formalin-fixed paraffin-embedded tissue. Pathol Int 68(11):633–635
Brat DJ, Aldape K, Colman H et al (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for “diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.” Acta Neuropathol 136(5):805–810
Capper D, Jones DTW, Sill M et al (2018) DNA methylation-based classification of central nervous system tumours. Nature 555(7697):469–474
Brat DJ, Aldape K, Colman H et al (2020) cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139(3):603–608
Suzuki H, Aoki K, Chiba K et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47(5):458–468
Brat DJ, Verhaak RG, Cancer Genome Atlas Research Network et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372(26):2481–2498
McDonald JM, See SJ, Tremont IW et al (2005) The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 104(7):1468–1477
Cahill DP, Louis DN, Cairncross JG (2015) Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. CNS Oncol 4(5):287–294
Morin GB, Chan JA, Cairncross JG, Marra MA (2012) Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 226(1):7–16
Aoki K, Nakamura H, Suzuki H et al (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20(1):66–77
Otani R, Uzuka T, Higuchi F et al (2018) IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis. Cancer Sci 109(7):2327–2335
van den Bent MJ, Dubbink HJ, Marie Y et al (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European organization for research and treatment of cancer brain tumor group. Clin Cancer Res 16(5):1597–1604
留言 (0)